Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Apozeal Pharmaceuticals Inc.
FDA Inspection
•Apozeal Pharmaceuticals Inc.•April 9, 2019

Apozeal Pharmaceuticals Inc. – FDA Inspection, Apr 9, 2019

Record Details

This FDA Inspection record concerns Apozeal Pharmaceuticals Inc., with an inspection on April 9, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Apozeal Pharmaceuticals Inc.
Inspection Date
April 9, 2019
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Christina K. Theodorou (FDA Associated Person)
  • Dandan Wang (Company Rep)
  • Lisa B. Orr (Issuing Officer)
View Company Profile

ID · a1f553bf-210b-4f01-81a3-d4276c44e2b1

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number
1085686
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued

FDA Citations

8
  1. 21 CFR 211.160(b)(3)Acceptance of drug products
  2. 21 CFR 211.63Equipment Design, Size and Location
  3. 21 CFR 211.192Extent of discrepancy, failure investigations
  4. 21 CFR 211.113(a)Procedures for non-sterile drug products
  5. 21 CFR 211.67(b)(3)Cleaning SOPs/instructions
  6. 21 CFR 211.192Investigations of discrepancies, failures
  7. 21 CFR 211.22(d)Procedures not in writing, fully followed
  8. 21 CFR 211.110(b)In-process conformity - examination, sample testing

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Apozeal Pharmaceuticals Inc.

8
DateClassificationOfficeProject area
October 15, 2025OAIPhiladelphia District OfficeDrug Quality Assurance
December 15, 2021NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
November 9, 2018NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
July 26, 2018OAIPhiladelphia District OfficeGeneric Drug Evaluation
February 7, 2018OAIPhiladelphia District OfficeGeneric Drug Evaluation
View all 8 other inspections on the company page
Other documents for Apozeal Pharmaceuticals Inc.
  • FDA Inspection 1287054 - 2025-10-15
  • FDA Inspection 1161191 - 2021-12-15
  • FDA Inspection 1073461 - 2018-11-09
  • FDA Inspection 1060369 - 2018-07-26
  • FDA Inspection 1040076 - 2018-02-07

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Apozeal Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.